ModernMedicine Resource Center More Topics

Targeted Therapy Resource Center

PCa immunotherapy: Response better when given before ADTAdministering sipuleucel-T (Provenge) before rather than after androgen deprivation therapy in men with biochemically recurrent prostate cancer appears to result in a more robust immunologic response, according to a recent study.
Prostate Ca: Immunotherapy consensus statement publishedStatement authors recommend using immunotherapy prior to an androgen receptor-targeted agent in men with metastatic castration-resistant prostate cancer.
High-grade bladder Ca: New data improve risk stratification“We need to identify those patients with high-grade T1 bladder cancer that are likely to recur or progress… and find additional options to prevent recurrence and progression in these patients,” said Joaquim Bellmunt, MD, PhD, in a presentation at the SUO annual meeting.
RCC: Multiple pathways provide therapeutic targetsRead highlights from a presentation by Toni K. Choueiri, MD, at the Society of Urologic Oncology annual meeting.
Immunotherapies move toward FDA approval for urothelial CaTwo late-stage immunotherapy drugs for the treatment of urothelial carcinoma reach regulatory, research milestones.
Next-gen sequencing panel for renal Ca earns CLIA approvalThe genomic profiling tool distinguishes among the dominant three malignant and one benign renal cancer subtypes.
Oral agent improves survival in advanced RCC patientsOnce-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor, significantly improves overall survival as well as progression-free survival and objective responses rates compared with everolimus (Afinitor) in previously treated patients with advanced renal cell carcinoma, according to final results from the phase III METEOR trial.
Bladder Cancer: Androgen receptor activation a potential therapeutic targetMultiple studies on exosomes, data from the IMvigor 210 trial of atezolizumab (TECENTRIQ), and research on prehabilitation for cystectomy were among the highlights in bladder cancer from the 2016 AUA annual meeting.
What anti-PD-L1 immunotherapy approval means for urologyUrologist Peter Black, MD, discusses the recent FDA approval of atezolizumab (TECENTRIQ) for the most common form of bladder cancer as well as a complementary diagnostic test.
A new castration-resistant prostate cancer entity?Urology Times SUO internship program member Brandon Manley, MD, reports on an SUO presentation highlighting several interesting findings on advanced prostate cancer with variant histology.